Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
[coats disease]
In
Coats
'
disease
,
the
most
recent
development
in
the
treatment
has
been
the
intravitreal
injection
of
anti-
VEGF
agents
.
The
purpose
of
this
article
was
to
evaluate
the
effect
of
intravitreal
bevacizumab
as
the
initial
treatment
for
Coats
'
disease
in
children
and
adults
.
The
study
included
14
pediatric
patients
and
five
adult
patients
with
Coats
'
disease
.
They
were
treated
with
intravitreal
bevacizumab
(
1
.
25
Â
mg
/
0
.
05
Â
ml
)
as
the
initial
treatment
,
combined
with
or
without
other
treatments
.
The
analyses
included
the
evaluation
of
basic
clinical
conditions
.
In
the
pediatric
group
,
after
a
mean
of
9
.
1
Â
months
of
follow-up
,
the
differences
in
visual
acuity
were
significant
for
the
comparisons
between
the
baseline
examination
and
the
follow-up
examinations
carried
out
at
weeks
6
,
12
,
and
24
after
the
baseline
(
P
 
=
 
0
.
006
,
P
 
=
 
0
.
004
,
P
 
=
 
0
.
005
respectively
)
.
Vitreoretinal
fibrosis
was
observed
in
three
patients
(
n
 
=
 
3
,
21
.
4
Â
%
)
,
among
whom
two
showed
fibrosis
before
treatment
.
All
of
the
pediatric
patients
showed
a
resolution
of
fluid
and
exudation
,
and
regression
of
the
telangiectasia
.
In
the
adult
group
,
after
a
mean
of
10
.
6
Â
months
of
follow-up
,
the
differences
in
visual
acuity
were
not
statistically
significant
(
P
 
>
 
0
.
05
)
between
the
baseline
and
follow-up
examinations
.
Vitreoretinal
fibrosis
(
n
 
=
 
2
,
40
Â
%
)
was
observed
in
two
patients
who
both
showed
fibrosis
before
treatment
.
All
of
the
adult
patients
showed
a
resolution
of
fluid
and
exudation
,
and
regression
of
the
telangiectasia
.
The
differences
in
the
change
of
BCVA
between
children
and
adults
were
not
significant
(
P
 
>
 
0
.
05
)
during
the
follow-up
examinations
.
The
intravitreal
injection
of
bevacizumab
as
the
initial
treatment
is
associated
with
a
measurable
gain
in
visual
acuity
in
patients
with
Coats
'
disease
.
Resolution
of
the
subretinal
fluid
and
exudation
,
and
regression
of
the
telangiectasia
were
observed
in
both
pediatric
and
adult
patients
.
Vitreoretinal
fibrosis
may
be
one
of
the
natural
courses
of
Coats
'
disease
,
and
it
remains
uncertain
whether
bevacizumab
accelerates
the
fibrosis
phenomenon
.
Diseases
Validation
Diseases presenting
"telangiectasia"
symptom
coats disease
cowden syndrome
cutaneous mastocytosis
hereditary cerebral hemorrhage with amyloidosis
kallmann syndrome
kindler syndrome
malignant atrophic papulosis
omenn syndrome
pendred syndrome
severe combined immunodeficiency
systemic capillary leak syndrome
triple a syndrome
waldenström macroglobulinemia
werner syndrome
This symptom has already been validated
